Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 2/20 | 0.43 |
| ▸ | CTSC | P53634 | 5/20 | 0.43 |
| ▸ | IDH2 | P48735 | 6/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28821019 | 0.89 | CTSC (0.45) | MTORCTSCIDH2TP53MAPT | |
| SCHEMBL16086165 | 0.88 | IDH2 (0.44) | MTORCTSCIDH2TP53MAPT | |
| SCHEMBL14978436 | 0.83 | CTSC (0.44) | MTORCTSCIDH2TP53MAPT | |
| SCHEMBL27930761 | 0.83 | MTOR (0.39) | MTORCTSCIDH2TP53MAPT | |
| SCHEMBL15615876 | 0.82 | MPO (0.51) | MTORCTSCTP53MAPTSMN1; SMN2 | |
| SCHEMBL15615888 | 0.80 | LMNA (0.53) | MTORIDH2TP53MAPT | |
| SCHEMBL15615882 | 0.79 | MAPT (0.52) | TP53MAPTSMN1; SMN2 | |
| SCHEMBL15615969 | 0.75 | CNR2 (0.58) | APP | |
| SCHEMBL16086154 | 0.74 | MTOR (0.43) | MTOR | |
| SCHEMBL2163621 | 0.71 | PIM1 (0.50) | CTSCIDH2TP53MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284315-B2 | Three-ring PI3K and/or mTOR inhibitor | ZUANZHU PHARMA CO., LTD. (CN) | 2016-03-15 | — | — | US | disclosed |
| US-9284315-B2 | Three-ring PI3K and/or mTOR inhibitor | ZUANZHU PHARMA CO., LTD. (CN) | 2016-03-15 | — | — | US | disclosed |
| US-20150166539-A1 | THREE-RING PI3K AND/OR MTOR INHIBITOR | Xuanzhu Pharma Co., Ltd. (CN) | 2015-06-18 | — | — | US | disclosed |
| US-20150166539-A1 | THREE-RING PI3K AND/OR MTOR INHIBITOR | Xuanzhu Pharma Co., Ltd. (CN) | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166539-A1 | THREE-RING PI3K AND/OR MTOR INHIBITOR | MTOR, RICTOR, AKT3 | MTOR 1/4885CTSC 3439/4885IDH2 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.